An update from NLS Pharmaceutics ( (NLSP) ) is now available.
NLS Pharmaceutics Ltd. announced the completion of a $3 million private placement financing and a $25 million equity facility agreement in March 2025. The company plans to use the proceeds for working capital, general corporate purposes, and expenses related to its merger with Kadimastem Ltd. These financial moves are expected to enhance NLS Pharmaceutics’ operational capabilities and strategic positioning in the pharmaceutical industry.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a pharmaceutical company based in Zurich, Switzerland, focusing on the development of innovative therapies for the treatment of rare and complex central nervous system disorders.
YTD Price Performance: -40.37%
Average Trading Volume: 2,435,918
Technical Sentiment Signal: Buy
Current Market Cap: $3.21M
Learn more about NLSP stock on TipRanks’ Stock Analysis page.